Authoritative new analysis links increased omega-3 intake to cardioprotection and improved cardiovascular outcomes.

Study indicates that EPA and DHA supplementation reduces multiple types of cardiovascular risk, according to Mayo Clinic Proceedings.

A new study published in Mayo Clinic Proceedings provides the most comprehensive analysis of the role of omega-3 dosage on cardiovascular prevention to date.

The research concludes that EPA and DHA omega-3 intake is associated with reduced risk of coronary heart disease (CHD) events, the cause of 7.4 million deaths globally each year, and reduced risk of myocardial infarction (heart attack), including fatal heart attack.

The researchers found that adding an extra 1000 mg of EPA and DHA per day decreased the risk of cardiovascular disease and heart attack even more: risk of cardiovascular disease events decreased by 5.8 percent and risk for heart attack decreased by 9.0 percent.

“Given the safety and diminished potential for interaction with other medications, the positive results of this study strongly suggest omega-3 supplements are a relatively low-cost, high impact way to improve heart health with few associated risks and should be considered as part of a standard preventive treatment for most patients with cardiovascular diseases and those recovering from myocardial infarction.”.

Reference: “Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials” by Aldo A.

Laukkanen, MD, PhD, 17 September 2020, Mayo Clinic Proceedings.

September 14, 2020

September 14, 2020

September 13, 2020

September 13, 2020

September 13, 2020